All basic science comes with limitations, just like human clinical trials (heterogeneity and limited scope of control, let’s not even talk about observational). But I don’t think it’s of very little use. I’m just talking generally, I didn’t go through the paper thoroughly to give a technical comment, but if a treatment exacerbates a pre-existing condition or triggers a condition in an at-risk model, I’d think it can be quite useful because such circumstances do occur plenty in humans.
All basic science comes with limitations, just like human clinical trials (heterogeneity and limited scope of control, let’s not even talk about observational). But I don’t think it’s of very little use. I’m just talking generally, I didn’t go through the paper thoroughly to give a technical comment, but if a treatment exacerbates a pre-existing condition or triggers a condition in an at-risk model, I’d think it can be quite useful because such circumstances do occur plenty in humans.